Beetroot for fatty liver has gained attention as a potential dietary intervention, but what does the evidence actually show? Fatty liver disease, or hepatic steatosis, affects approximately one in three UK adults and occurs when excess fat accumulates in liver cells. Whilst beetroot contains bioactive compounds such as betalains, betaine, and dietary nitrates that show promise in laboratory studies, robust human evidence for its role in treating fatty liver disease remains limited. This article examines the current scientific understanding of beetroot's nutritional properties, reviews the available evidence for its use in managing fatty liver, and explains how it fits within evidence-based lifestyle modifications and medical management recommended by NICE and UK hepatology guidance.

What Is Fatty Liver Disease and How Does It Develop?

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. On histology, this is defined as fat in more than 5% of hepatocytes; imaging techniques such as MRI-PDFF use a threshold of more than 5% fat fraction. The condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), which affects individuals who consume little to no alcohol, and alcoholic fatty liver disease (AFLD), directly related to excessive alcohol intake. NAFLD has become increasingly prevalent in the UK, affecting approximately one in three adults, making it the most common chronic liver condition in developed nations. (Note: international nomenclature is evolving to metabolic dysfunction-associated steatotic liver disease [MASLD] and steatohepatitis [MASH], though UK guidance and NHS resources currently use NAFLD and NASH.)

The pathophysiology of fatty liver disease involves complex metabolic disturbances. In NAFLD, insulin resistance plays a central role, causing the liver to accumulate triglycerides rather than processing them efficiently. When the body cannot effectively use insulin to regulate blood glucose, the liver compensates by converting excess carbohydrates into fat. This process is exacerbated by obesity, type 2 diabetes, dyslipidaemia, and metabolic syndrome—conditions that frequently coexist with fatty liver disease.

Key risk factors include:

• Obesity, particularly central adiposity

• Type 2 diabetes mellitus

• High cholesterol and triglycerides

• Sedentary lifestyle and poor dietary habits

• Rapid weight loss or malnutrition

• Certain medicines (e.g., corticosteroids, tamoxifen, methotrexate, amiodarone, valproate) are associated with steatosis or steatohepatitis

Most individuals with simple fatty liver remain asymptomatic, with the condition often discovered incidentally during imaging for unrelated concerns. Importantly, liver function tests (LFTs) may be entirely normal in NAFLD, so normal blood results do not exclude the condition. A proportion of people—estimated at around 10–20%—may progress to non-alcoholic steatohepatitis (NASH), characterised by inflammation and hepatocyte damage. Without intervention, NASH can advance to fibrosis, cirrhosis, and hepatocellular carcinoma. Early detection and risk stratification are crucial. In the UK, NICE guidance (NG49) recommends using the FIB-4 score (age-adjusted) as the first-line tool to assess fibrosis risk, with the Enhanced Liver Fibrosis (ELF) test for those at indeterminate or high risk (ELF ≥10.51 indicates advanced fibrosis). Lifestyle modification remains the cornerstone of preventing disease progression and preserving hepatic function.

Beetroot Nutritional Properties and Potential Mechanisms

Beetroot (Beta vulgaris) is a nutrient-dense root vegetable that has attracted interest for its potential role in supporting overall health, including liver health, though robust human evidence specific to fatty liver disease remains limited. This vibrant vegetable contains an array of bioactive compounds. Betalains, the pigments responsible for beetroot's distinctive colour, possess antioxidant and anti-inflammatory properties in laboratory studies. These compounds, particularly betanin and vulgaxanthin, have been shown to neutralise free radicals in experimental models, and oxidative stress is recognised as a contributor to liver damage in fatty liver disease.

Beetroot is exceptionally rich in dietary nitrates, which the body converts to nitric oxide, a molecule that improves vascular function and blood flow. Whether enhanced circulation meaningfully benefits liver tissue in humans with NAFLD is not established. Additionally, beetroot contains betaine (trimethylglycine), a compound involved in methylation reactions. Betaine assists in the conversion of homocysteine to methionine, a process hypothesised to influence hepatic lipid metabolism, though clinical evidence in NAFLD is limited and mixed.

The nutritional profile of beetroot, per 100 g (based on UK food composition data), includes:

• Folate (109 μg, approximately 27% of the reference nutrient intake)

• Vitamin C (4.9 mg)

• Potassium (325 mg)

• Dietary fibre (2.8 g)

• Manganese and iron in modest amounts

• Energy: 43 kcal

The fibre content supports digestive health and may influence gut microbiota composition, which emerging research suggests plays a role in NAFLD development. The low energy density makes beetroot a useful component of weight management strategies. It is important to note that effects observed with isolated compounds (such as betaine supplements) do not necessarily translate to whole beetroot consumption. Beetroot can be a valuable part of a varied, vegetable-rich diet, but should not be viewed as a specific treatment for fatty liver disease.

Evidence for Beetroot in Managing Fatty Liver

The scientific evidence supporting beetroot's role in managing fatty liver disease is limited and derives primarily from preclinical studies, with only a small number of human trials examining isolated beetroot components rather than whole beetroot. Animal studies have demonstrated that beetroot extract and betaine supplementation can reduce hepatic steatosis, decrease inflammatory markers, and improve liver enzyme profiles in rodent models of NAFLD. These studies suggest potential mechanisms including reduced oxidative stress, improved lipid metabolism, and decreased hepatic triglyceride accumulation. However, animal findings do not reliably predict human clinical benefit.

A small number of randomised controlled trials have examined betaine supplementation (a key beetroot component) in humans with NAFLD or NASH. Results have been mixed and inconclusive. One trial involving patients with NASH used betaine supplementation (20 g daily for 12 months) and reported improvements in steatosis grade and reductions in serum aminotransferase levels compared to placebo, though the study was small and had methodological limitations. Other trials have shown inconsistent or no significant histological benefit. Overall, the quality of evidence is low to very low, with limitations including small sample sizes, heterogeneous methodologies, and lack of long-term follow-up.

Important considerations regarding the evidence:

• Most human studies have examined isolated betaine supplements rather than whole beetroot consumption, and findings cannot be directly extrapolated

• Optimal dosing, duration, and form (raw, cooked, juice) for any potential liver benefit remain unknown

• Individual responses may vary based on disease severity, genetic factors, and concurrent lifestyle modifications

• Neither beetroot nor betaine supplementation is recommended by NICE or European liver guidelines (EASL) for the treatment of NAFLD or NASH outside research settings

• There is no established evidence that beetroot consumption can reverse established fatty liver disease

Whilst beetroot shows biological plausibility for supporting general health, it should not be considered a standalone or proven treatment for fatty liver disease. The current evidence suggests it may be a beneficial component of a varied, plant-rich diet within a comprehensive lifestyle intervention, but it cannot replace established medical management. Further large-scale, well-designed human trials are needed to definitively establish whether beetroot or its components have a therapeutic role, and to determine optimal dosing and long-term safety in people with fatty liver disease.

How to Include Beetroot Safely in Your Diet

Incorporating beetroot into your diet as part of a balanced, vegetable-rich eating pattern can be achieved through various practical methods, though there is no proven therapeutic dose for liver health. Fresh beetroot can be consumed raw (grated in salads), roasted, boiled, or steamed. The NHS Eatwell Guide and 5 A Day recommendations suggest an 80 g portion of vegetables counts as one portion; aim to include a variety of vegetables, including beetroot, as part of at least five portions of fruit and vegetables daily. Cooking methods may affect nutrient content, though specific effects on betalains and other compounds are not fully characterised.

Beetroot juice has gained popularity for its concentrated nutrient content. However, juicing removes beneficial fibre and concentrates natural sugars, which may be counterproductive for individuals with insulin resistance or diabetes—common conditions in people with fatty liver disease. The NHS advises that fruit and vegetable juice or smoothies should be limited to a combined total of 150 ml per day (counting as a maximum of one portion of your 5 A Day), and should be consumed with meals to moderate blood glucose impact. Some individuals experience beeturia (red-coloured urine) or red stools after beetroot consumption, which is harmless. However, if red urine or dark stools persist, or are accompanied by pain, dizziness, or other symptoms, seek medical advice to rule out other causes.

Safety considerations and when to seek advice:

• Kidney stones: Beetroot is high in oxalates, which may increase risk in individuals with a history of calcium oxalate kidney stones; discuss with your GP if this applies to you

• Low blood pressure: The nitrate content may lower blood pressure; if you take medicines for high blood pressure, monitor your blood pressure and inform your GP

• Diabetes management: Monitor blood glucose responses, particularly with beetroot juice, and discuss any concerns with your diabetes care team

• Chronic kidney disease (CKD): Beetroot is relatively high in potassium; if you have advanced CKD or have been advised to limit potassium, discuss beetroot intake with your GP or dietitian

• Gastrointestinal sensitivity: Some people experience bloating or digestive discomfort

Beetroot supplements (betaine, beetroot powder, or extract) are available but are regulated as foods in the UK (by the Food Standards Agency), not to the same standards as medicines, and quality and content can vary. There is no established evidence for their use in fatty liver disease. If considering supplements, choose reputable brands and discuss with your GP or a registered dietitian, particularly if you take any medicines. Always inform your healthcare provider about any supplements you use, as they may interact with medicines or affect laboratory test results. If you experience a suspected side effect from a beetroot-containing supplement or any medicine, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk. Beetroot should complement, not replace, evidence-based medical treatments and lifestyle modifications for fatty liver disease.

Medical Treatments and Lifestyle Changes for Fatty Liver

The cornerstone of fatty liver disease management remains lifestyle modification, as no medicine is currently licensed specifically for NAFLD in the UK. NICE guidance (NG49) emphasises that weight loss of 7–10% of body weight can significantly reduce hepatic steatosis, improve inflammatory markers, and potentially reverse early-stage disease. This should be achieved gradually (0.5–1 kg per week) through sustainable dietary changes and increased physical activity, as rapid weight loss may paradoxically worsen liver inflammation.

Evidence-based lifestyle interventions include:

• Dietary modification: A Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil, whilst limiting refined carbohydrates, saturated fats, and processed foods, is supported by evidence

• Physical activity: Aim for at least 150 minutes of moderate-intensity aerobic exercise weekly (such as brisk walking, cycling, or swimming), plus muscle-strengthening activities on two or more days per week, in line with UK Chief Medical Officers' guidelines

• Alcohol: For people with simple NAFLD and no advanced fibrosis, the UK Chief Medical Officers advise that if you drink alcohol regularly, you should not exceed 14 units per week, spread over three or more days, with several alcohol-free days. However, complete abstinence from alcohol is strongly advised if you have NASH, advanced fibrosis, or cirrhosis, as any alcohol consumption may accelerate disease progression

• Weight management: Structured programmes with dietetic support are recommended for those with a BMI ≥25 kg/m²; bariatric or metabolic surgery may be considered for people with severe obesity after multidisciplinary team assessment

For patients with type 2 diabetes and NAFLD, optimising blood glucose control is essential. Metformin, whilst not specifically hepatoprotective, improves insulin sensitivity and supports weight management. Newer agents such as GLP-1 receptor agonists (liraglutide, semaglutide) have shown promise in reducing liver fat content in clinical trials, though they are not yet licensed for NAFLD treatment in the UK; their use should be guided by diabetes and obesity indications as per their Summary of Product Characteristics (SmPC). Pioglitazone, a thiazolidinedione, has demonstrated histological improvement in some studies of NASH, but carries risks including weight gain, fluid retention and heart failure, increased fracture risk (particularly in women), and a small increased risk of bladder cancer (MHRA Drug Safety Update). Its use is restricted to carefully selected patients under specialist supervision and is not routinely recommended.

Managing cardiovascular risk is a key part of NAFLD care, as people with NAFLD have increased cardiovascular morbidity and mortality. Statins are safe and indicated for managing dyslipidaemia and reducing cardiovascular risk in people with NAFLD, unless contraindicated, and do not worsen liver disease. Blood pressure and lipid management should follow standard UK guidance.

Risk stratification and monitoring are essential. NICE NG49 recommends using the FIB-4 score (age-adjusted) as the first-line tool to assess fibrosis risk in primary care. For those at indeterminate or high risk, the Enhanced Liver Fibrosis (ELF) test should be used; an ELF score ≥10.51 indicates advanced fibrosis. Referral to specialist hepatology services is indicated for:

• Persistently abnormal liver function tests despite lifestyle modification

• Evidence of advanced fibrosis (ELF ≥10.51, or FIB-4 suggesting high risk in the appropriate age context)

• Clinical signs of chronic liver disease or portal hypertension (e.g., jaundice, ascites, splenomegaly, spider naevi)

• Diagnostic uncertainty

Patients with advanced fibrosis or cirrhosis require specialist hepatology input and regular surveillance for complications, including hepatocellular carcinoma (typically six-monthly ultrasound ± alpha-fetoprotein, according to local protocols) and portal hypertension. Regular monitoring through liver function tests, non-invasive fibrosis assessment (such as FibroScan or ELF), and metabolic screening enables early detection of disease progression. Patients should maintain regular contact with their GP, attend scheduled reviews, and seek medical advice promptly if experiencing new symptoms such as jaundice, abdominal swelling, confusion, unexplained bruising, or vomiting blood. A multidisciplinary approach involving GPs, hepatologists, dietitians, diabetes specialists, and other healthcare professionals optimises outcomes in this increasingly prevalent condition.

Frequently Asked Questions